Browsing by Author "Shaik, Riyazuddin M."
Now showing items 1-5 of 5
-
Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections
Chemaitelly, Hiam; Ayoub, Houssein H.; AlMukdad, Sawsan; Faust, Jeremy S.; Tang, Patrick; Coyle, Peter; Yassine, Hadi M.; Al Thani, Asmaa A.; Al-Khatib, Hebah A.; Hasan, Mohammad R.; Al-Kanaani, Zaina; Al-Kuwari, Einas; Jeremijenko, Andrew; Kaleeckal, Anvar H.; Latif, Ali N.; Shaik, Riyazuddin M.; Abdul-Rahim, Hanan F.; Nasrallah, Gheyath K.; Al-Kuwari, Mohamed G.; Butt, Adeel A.; Al-Romaihi, Hamad E.; Al-Thani, Mohamed H.; Al-Khal, Abdullatif; Bertollini, Roberto; Abu-Raddad, Laith J.... more authors ... less authors (2023 , Article)In October of 2022, Qatar introduced COVID-19 bivalent vaccination for persons ≥ 12 years using the 50-μg mRNA-1273.214 vaccine combining SARS-CoV-2 ancestral and omicron BA.1 strains.1 We estimated this vaccine’s effectiveness ... -
Covid-19 Vaccine Protection among Children and Adolescents in Qatar.
Chemaitelly, Hiam; AlMukdad, Sawsan; Ayoub, Houssein H; Altarawneh, Heba N; Coyle, Peter; Tang, Patrick; Yassine, Hadi M; Al-Khatib, Hebah A; Smatti, Maria K; Hasan, Mohammad R; Al-Kanaani, Zaina; Al-Kuwari, Einas; Jeremijenko, Andrew; Kaleeckal, Anvar H; Latif, Ali N; Shaik, Riyazuddin M; Abdul-Rahim, Hanan F; Nasrallah, Gheyath K; Al-Kuwari, Mohamed G; Al-Romaihi, Hamad E; Butt, Adeel A; Al-Thani, Mohamed H; Al-Khal, Abdullatif; Bertollini, Roberto; Abu-Raddad, Laith J... more authors ... less authors ( Massachusetts Medical Society , 2022 , Article)The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but in different antigen doses. We assessed the real-world ... -
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
Abu-Raddad, Laith J; Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Yassine, Hadi M; Al-Khatib, Hebah A; Smatti, Maria K; Tang, Patrick; Hasan, Mohammad R; Coyle, Peter; Al-Kanaani, Zaina; Al-Kuwari, Einas; Jeremijenko, Andrew; Kaleeckal, Anvar H; Latif, Ali N; Shaik, Riyazuddin M; Abdul-Rahim, Hanan F; Nasrallah, Gheyath K; Al-Kuwari, Mohamed Ghaith; Butt, Adeel A; Al-Romaihi, Hamad Eid; Al-Thani, Mohamed H; Al-Khal, Abdullatif; Bertollini, Roberto... more authors ... less authors ( Massachusetts Medical Society , 2022 , Article)Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to expedited ... -
Protection against Reinfection with the Omicron BA.2.75 Subvariant
Chemaitelly, Hiam; Tang, Patrick; Coyle, Peter; Yassine, Hadi M.; Al-Khatib, Hebah A.; Smatti, Maria K.; Hasan, Mohammad R.; Ayoub, Houssein H.; Altarawneh, Heba N.; Al-Kanaani, Zaina; Al-Kuwari, Einas; Jeremijenko, Andrew; Kaleeckal, Anvar H.; Latif, Ali N.; Shaik, Riyazuddin M.; Abdul-Rahim, Hanan F.; Nasrallah, Gheyath K.; Al-Kuwari, Mohamed G.; Butt, Adeel A.; Al-Romaihi, Hamad E.; Al-Thani, Mohamed H.; Al-Khal, Abdullatif; Bertollini, Roberto; Abu-Raddad, Laith J.... more authors ... less authors ( Massachusetts Medical Society , 2023 , Other)The BA.2.75 sublineage of the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may escape neutralizing antibodies. The BA.2.75 sublineage (primarily the BA.2.75.2 subvariant) ... -
Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant
Chemaitelly, Hiam; Coyle, Peter; Kacem, Mohamed Ali Ben; Ayoub, Houssein H.; Tang, Patrick; Hasan, Mohammad R.; Yassine, Hadi M.; Al Thani, Asmaa A.; Al-Kanaani, Zaina; Al-Kuwari, Einas; Jeremijenko, Andrew; Kaleeckal, Anvar H.; Latif, Ali N.; Shaik, Riyazuddin M.; Abdul-Rahim, Hanan F.; Nasrallah, Gheyath K.; Al-Kuwari, Mohamed Ghaith; Butt, Adeel A.; Al-Romaihi, Hamad E.; Al-Thani, Mohamed H.; Al-Khal, Abdullatif; Bertollini, Roberto; Abu-Raddad, Laith J.... more authors ... less authors ( Oxford University Press , 2024 , Article)Evidence at the level of neutralizing antibodies suggests that the SARS-CoV-2 JN.1 variant demonstrates increased immune evasion compared to its parent lineage BA.2.86 and to recently circulating variants, such as XBB.1.5 ...